NewAmsterdam Pharma Company N.V. (NAMS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NewAmsterdam Pharma Company N.V., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NewAmsterdam Pharma Company N.V. (NAMS) has returned -8.75% so far this year and 56.38% over the past 12 months.

Based on dividend-adjusted daily data since Nov 23, 2022, NAMS's average daily return is +0.23%, while the average monthly return is +4.17%. At this rate, your investment would double in approximately 1.4 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jan 2024 with a return of +83.3%, while the worst month was Nov 2022 at -21.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NAMS closed higher 50% of trading days. The best single day was Dec 10, 2024 with a return of +41.4%, while the worst single day was Jan 31, 2023 at -24.5%.

NewAmsterdam Pharma Company N.V. has an annualized alpha of 57.29%, beta of 0.84, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 25, 2022.

• This stock captured 143.54% of S&P 500 Index gains but only 14.17% of its losses — a favorable profile for investors.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NAMS ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for NewAmsterdam Pharma Company N.V. (NAMS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NewAmsterdam Pharma Company N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NewAmsterdam Pharma Company N.V. was 66.23%, occurring on Oct 25, 2023. Recovery took 58 trading sessions.

The current NewAmsterdam Pharma Company N.V. drawdown is 22.77%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NewAmsterdam Pharma Company N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NewAmsterdam Pharma Company N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.